已收盤 11-16 16:00:00 美东时间
0.000
0.00%
8月9日,中国国家药监局(NMPA)药品审评中心(CDE)官网公示,信达生物(01801)1类新药IBI3001新药临床试验申请获得受理。
2024-08-09 10:28
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including
2023-10-13 04:36
11 月15 日晚,神州细胞发布公告,称其自主研发的 2 价和 4 价重组新冠病毒疫苗 III 期安全性和免疫原性临床试验与 mRNA 疫苗头对头比较的期中分析...
2022-11-17 09:28